Cutting Edge（文献解説）

Long-Term Effect of Tafamidis on Clinical Parameters and Prognostic Predictors in Patients With Transthyretin Amyloid Cardiomyopathy. Kuyama N, Izumiya Y, Takashio S, et al. Circ J. 2025 ; 89 : 421-31. Long-Term Efficacy and Safety of Acoramidis in ATTR-CM: Initial Report From the Open-Label Extension of the ATTRibute-CM Trial. Judge DP, Gillmore JD, Alexander KM, et al. Circulation. 2025 ; 151 : 601-11. Vutrisiran in Patients with Transthyretin Amyloidosis with Cardiomyopathy. Fontana M, Berk JL, Gillmore JD, et al. N Engl J Med. 2025 ; 392 : 33-44. Kidney Outcomes in Transthyretin Amyloid Cardiomyopathy. Ioannou A, Razvi Y, Porcari A, et al. JAMA Cardiol. 2025 ; 10 : 50-8. CRISPR-Cas9 Gene Editing with Nexiguran Ziclumeran for ATTR Cardiomyopathy. Fontana M, Solomon SD, Kachadourian J, et al. N Engl J Med. 2024 ; 391 : 2231-41. Structure-Based Probe Reveals the Presence of Large Transthyretin Aggregates in Plasma of ATTR Amyloidosis Patients. Pedretti R, Wang L, Yakubovska A, Zhang QS, et al. JACC Basic Transl Sci. 2024 ; 9 : 1088-100. A real-life study of daratumumab combinations in newly diagnosed patients with light chain (AL) amyloidosis. Bellofiore C, Benvenuti P, Mina R, et al. Hematol Oncol. 2024 ; 42 : e3289. Guidelines for high dose chemotherapy and stem cell transplantation for systemic AL amyloidosis: EHA-ISA working group guidelines. Sanchorawala V, Boccadoro M, Gertz M, et al. Amyloid. 2022 ; 29 : 1-7.